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Dental management considerations for the
patient with an acquired coagulopathy. 
Part 1: Coagulopathies from systemic disease
P. B. Lockhart1, J. Gibson2, S. H. Pond3 and J. Leitch4
Current teaching suggests that many patients are at risk for prolonged bleeding during and following invasive dental
procedures, due to an acquired coagulopathy from systemic disease and/or from medications. However, treatment standards
for these patients often are the result of long-standing dogma with little or no scientific basis. The medical history is critical
for the identification of patients potentially at risk for prolonged bleeding from dental treatment. Some time-honoured
laboratory tests have little or no use in community dental practice. Loss of functioning hepatic, renal, or bone marrow tissue
predisposes to acquired coagulopathies through different mechanisms, but the relationship to oral haemostasis is poorly
understood. Given the lack of established, science-based standards, proper dental management requires an understanding of
certain principles of pathophysiology for these medical conditions and a few standard laboratory tests. Making changes in
anticoagulant drug regimens are often unwarranted and/or expensive, and can put patients at far greater risk for morbidity
and mortality than the unlikely outcome of postoperative bleeding. It should be recognised that prolonged bleeding is a rare
event following invasive dental procedures, and therefore the vast majority of patients with suspected acquired
coagulopathies are best managed in the community practice setting.
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Dental patients often present with a med-
ical history that suggests the potential
for clinically significant intraoperative
bleeding, which might be defined as
blood obscuring the operative site and
interfering with carrying out a given
procedure, or blood loss sufficient to
require transfusion. Several hours of
minor postoperative bleeding is of little
concern following procedures such as
dental extractions, but there is no com-
monly accepted definition of what con-
stitutes prolonged or clinically signifi-
cant postoperative bleeding. It could be
defined as that which: 
1. Continues beyond 12 hours;
2. Causes the patient to call or return to the
dental practitioner or to the accident
and emergency department;
3. Results in the development of a large
haematoma or ecchymosis within the
oral soft tissues; or 
4. Requires a blood transfusion. 
Most episodes cause concern or incon-
venience to the patient, and rarely require a
return to the dental surgery or local acci-
dent and emergency department. 
Coagulopathies that predispose to oral
bleeding can be divided into two broad
categories — inherited and acquired. This
two part review covers acquired coagu-
lopathies that arise from disease, or med-
ications, or both. Disease-related bleed-
ing disorders result most often from
hepatic, renal, and bone marrow disor-
ders, which have varying effects on the
haemostatic process (Table 1). Bleeding
problems from medications will be cov-
ered in a subsequent paper. An under-
standing of the basic features of the coag-
ulation cascade is helpful for an
appreciation of the common elements of
inherited and acquired coagulopathies
and how medications and disease affect
the coagulation cascade (Fig. 1).1
The challenge for the dental practitioner
is to: 
● There is little scientific basis for treatment standards for patients with coagulopathies. 
● The medical history is critical to the identification of patients at risk for prolonged bleeding. 
● Laboratory tests ordered must be specific to the specific bleeding disorder.
● The relationship between oral bleeding and liver, kidney and bone marrow disease is poorly
understood.
● There is a need for research on the dental management of patients with coagulopathies.
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1. Determine the relative likelihood of clin-
ically significant bleeding from a variety
of invasive procedures for patients with
liver, kidney, or bone marrow disorders;
and 
2. Put into perspective the risk for, and
outcome of, clinically significant bleed-
ing versus the risk associated with alter-
ing the patient's medical management
(eg anticoagulant dosage). 
This issue becomes more complex and
even less science-based when a patient has
more than one source of a coagulopathy,
such as the chronic alcoholic who takes an
anticoagulant for cardiovascular disease.
Community practice standards are
based on a large volume of chapters, case
reports, retrospective studies, opinion
papers, and unofficial guidelines, few of
which are based on data from clinical trials.
The ordering of laboratory tests and mak-
ing changes in anticoagulant drug regi-
mens are often unwarranted and/or expen-
sive, and can put patients at far greater risk
for morbidity and mortality than the
unlikely outcome of postoperative bleed-
ing. The dental management of these
patients is less complicated than commonly
thought, and can usually be accomplished
in the primary care setting without the need
for changes in medical management, refer-
ral to a specialist, or hospitalisation.2,3
This paper summarises common acquired
coagulopathies due to systemic disease, and
proposes guidelines for the evaluation and
management of this often-challenging
group of patients. The process of patient
management begins with the medical and
dental history and an assessment of the need
for medical consultation and laboratory
studies.
THE MEDICAL HISTORY
The appropriate medical history is dictated
by the clinical situation, and is a prerequisite
for the proper management of all dental
patients, in particular those who may be at
risk for oral bleeding. Information gained
from the patient will usually suggest the
nature and severity of the coagulopathy,
and this may be all that is needed prior to an
invasive dental procedure. Standard medical
history questionnaires can be used to gather
preliminary information as a starting point
for a more focused verbal questioning. Such
screening forms should have questions con-
cerning current and past problems with kid-
neys, liver, bone marrow, malignant disease,
and the use of specific medications thought
to cause a coagulopathy. Some patients will
have difficulty completing history forms
due to a poor understanding or expression
Table I Common systemic diseases that may interfere with haemostasis
Disease Common causes Resulting coagulopathy
Renal failure Diabetes mellitus Inhibition of adhesion and primary
and uraemia Glomerulonephritis aggregation of platelets from glycoprotein
Pyelonephritis IIb-IIIa defect
Hypertension
Hepatic failure Alcohol abuse Obstructive jaundice — impedes Vit K
Hepatitis B and C delivery to the liver — loss of factors II,
Cancer (eg hepatocellular VII, IX, X
carcinoma) Loss of hepatic tissue and all clotting
factors except VIII and von Willebrand
factor
Bone marrow Alcohol abuse Reduced number of functioning platelets
failure Cancer (eg leukemia) Anaemia from bone marrow suppression
Myelosuppressive
medications (eg cancer
chemotherapy)
Uraemia from renal failure
INTRINSIC PATHWAY EXTRINSIC PATHWAY
Foreign Surface Vessel or Tissue Injury
XII XIIa
XIaXI
IX IXa
XIIIaVIII
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VIIVIIIa
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Fig. 1 The coagulation
cascade 
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of written English. It should be remembered
that the illiteracy rate in the UK is higher in
some areas, than others.
When patients give a history suggestive
of abnormal bleeding, the following issues
should be resolved:
1. Does the bleeding episode meet at least
one of the criteria mentioned above for
clinically significant postoperative
bleeding?
2. Was it due to local factors such as pre-
existing infection, localised trauma,
rinsing, spitting, or smoking cigarettes;
or was it spontaneous, which is rare but
might represent a clotting disorder of
systemic origin?
3. If it suggests a systemic bleeding disor-
der, does it represent an acquired (eg
drug related) or inherited coagulopathy?
4. Does it suggest a coagulopathy with one
or more causes?
Although pre-existing infection is
reported to be the most common cause of
an isolated episode of prolonged bleeding
following tooth extraction, patients must
be fully questioned regarding the circum-
stances.4 The following specific points in
the medical history should alert the practi-
tioner to a potential problem:
1. Previous diagnosis of a bleeding ten-
dency (eg epistaxis (nose bleed), easy
bruising);
2. Prolonged bleeding after nondental sur-
gical procedures (eg tonsillectomy);
3. Bleeding lasting more than 24 hours or
requiring a transfusion;
4. Hospital attendance and/or admission
for postoperative bleeding;
5. Use of medications known to interfere
with coagulation (eg warfarin);
6. Bleeding that begins some days after the
procedure (eg haemophilia); and
7. Chronic and excessive alcohol intake
(record type, volume consumed/week,
and duration in years). Although it can
be a difficult subject, it is important to
know about the volume of alcohol con-
sumed per week and the duration in
years. Heavy alcohol consumption is a
common cause of coagulopathy,5 and it
can be enhanced by the use of over-the-
counter medications (eg NSAIDs).
A positive response to any of the above
questions should lead the dental practition-
er to pursue further details until a decision
can be made regarding the need for labora-
tory testing and medical consultation, or a
determination that there is no reason for
concern.6 Each individual coagulopathy,
whether from medication or systemic dis-
ease, dictates specific questions and med-
ical evaluation (eg laboratory tests) to
determine nature and severity. A more sig-
nificant problem arises if there are multiple
coagulopathies. Although single coagu-
lopathies rarely result in clinically signifi-
cant oral bleeding, multiple coagulopathies
must be evaluated individually and then be
considered together, as two relatively
insignificant coagulopathies can result in
prolonged intra- or post-operative haem-
orrhage. Examples include: 
1. Patients with chronic renal failure who
takes aspirin and/or another anticoagu-
lant for cardiovascular disease or hyper-
coagulability from nephrotic syndrome
2. Patients with alcoholism affecting both
liver and bone marrow who take
NSAIDs or another platelet inhibitor as
prophylaxis for coronary artery disease.
In addition to the medical history, the
clinical examination of the oral mucosa
may reveal signs of an undiagnosed bleed-
ing disorder. For example, ecchymosis
(superficial bleeding under the mucosa)
and haematomas (a mass of extravasated
blood under the mucosa) suggest a coagu-
lopathy, especially in the absence of trau-
ma. Petechiae (small hemorrhagic spots
under the mucosa) and prolonged bleeding
from minor wounds suggest a problem
with platelets (quantitative or qualitative)
or with blood vessel integrity.
LABORATORY STUDIES
Specific laboratory tests are often recom-
mended to help determine the potential for
prolonged bleeding from surgical proce-
dures in patients with hepatic, renal, and
bone marrow disorders (Tables 2–4). His-
torically, the standard battery of laboratory
tests included the bleeding time (BT), pro-
thrombin time (PT), partial thromboplastin
time (PTT), platelet count, and Internation-
al Normalised Ratio (INR). The INR and PTT
will be discussed in a companion paper, as
they relate primarily to coagulopathies
from warfarin and heparin respectively.
Other tests, such as blood urea, serum crea-
tinine, creatinine clearance, haemoglobin,
serum albumin, and bilirubin are common-
ly thought to be of some value, but they
have limited use in dental practice because
cut-off values for safe treatment have not
been established. Laboratory screening
tests helpful in the evaluation of patients
with renal, liver or bone marrow disease
who may be at risk for bleeding are:
Bleeding time test
The standard method of determining
platelet function is to use one of the tech-
nique-sensitive bleeding time (BT) tests.
Refinements in the technique of perform-
ing a BT since it was first described in 1910
have resulted in a test that is often used as a
preoperative screen for the potential for
bleeding. The template BT test involves
applying a blood pressure cuff to the arm
and making a standardised incision on the
forearm with a template (small blade). The
wound is then carefully blotted on a specif-
ic schedule, and the time it takes for the
bleeding to stop is recorded in minutes.
One hospital reported that over 1,900 pre-
operative BTs were ordered in a 6-month
period for patients felt to be at risk for
bleeding, 6% of which were abnormal.7 It
has been estimated that the misuse of the
BT test in the Unites States results in a cost
of 114 million dollars (about 75 million
pounds sterling) each year.8 Abnormally
long bleeding time test results can have
several causes, such as abnormal skin and
vascular tone, thrombocytopenia, acquired
abnormalities of platelet function (eg
aspirin use), fibrinolysis, anaemia, uraemia,
liver disease, and von Willebrand factor
deficiency, as well as errors in technique of
performing this test.7,9–11 Although current
Table 2 Modified Child-Pugh classification for cirrhosis17 (units are US)
Numerical score
1 2 3
Parameter
Ascites None Slight Moderate/severe
Encephalopathy None Slight/moderate Moderate/severe
Bilirubin (mg/dL) < 2.0 2–3 > 3.0
Albumin (mg/L) > 3.5 2.8–3.5 < 2.8
Prothrombin time 1–3 4–6 > 6.0
(seconds increased)
Total numerical score Child-Pugh class
5–6 A
7–9 B
10–15 C
Reprinted by permission of W. B. Saunders Company
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standard of care suggests that the use of a
BT test and its correlations with postopera-
tive bleeding at non-oral sites, applies to
invasive dental procedures,12 there are no
prospective studies to confirm this. The BT
test is not normally performed in the UK,
and there is no clear indication for its use
in community dental practice.
Prothrombin time
The presurgical prothrombin time (PT) is
an example of a time-honoured laborato-
ry test commonly used to evaluate
patients with liver disease, as it measures
extrinsic pathway factors (I, II, V, VII, X),
three of which (II, VII, X) are vitamin K
dependent (Fig. 1). This test is performed
by mixing calcium and thromboplastin
with citrated plasma and measuring the
time it takes to coagulate. Thromboplastin
is a phospholipid-protein extract of ani-
mal tissues that contains the tissue factor
and the phospholipid necessary to provide
the activation of factor X by factor VII.13
In the past this test was not standardised,
as different commercially-produced
thromboplastins were used throughout
the world. This resulted in varying degrees
of anticoagulation, even with identical
PTs. Nevertheless, the PT test is useful to
estimate the degree of liver damage and
the propensity for bleeding, keeping in
mind that it is not a linear relationship. A
large portion of the liver (around 30–50%)
must be destroyed to be reflected in an
elevated PT test result, and therefore a
slightly increased PT test likely represents
significant liver damage.
Platelet count
The platelet count is a measure of the num-
ber of platelets in the systemic circulation,
with a normal range of 150,000–450,000/µl
(Table 3). A low platelet count (thrombocy-
topenia) can result from destruction (eg
drug poisoning from alcohol, hyper-
splenism from liver disease) or a decreased
production (eg leukaemia, drugs). Although
this test gives little or no information con-
cerning the viability or functionality of
platelets, there are generally accepted
platelet count ranges that represent vary-
ing degrees of thrombocytopenia and risk
for bleeding (Table 4). Certain drugs and
systemic disease can affect platelets both
quantitatively and qualitatively, as dis-
cussed under specific diseases above.
Creatinine, blood urea, and creatinine
clearance tests
Although the creatinine and blood urea
tests give a measure of impaired renal
function, they are not useful in dental
practice as it is not known what test results
represent a clinically significant risk for
oral bleeding.14,15 A creatinine of 265–355
µmol/L suggests the possibility of a prob-
lem, but at 530–620 µmol/L the likelihood
of prolonged oral bleeding becomes a con-
cern. Creatinine clearance (CRCL) test is
often cited as a gold standard for the degree
of renal failure, but test results may be
inaccurate due to the common (20%–30%)
problem of an incomplete 24-hour urine
collection. 
The CRCL test could serve as a rough
predictor for prolonged oral bleeding,
although there are no prospective studies
to demonstrate this relationship. Patients
with a potential for oral bleeding would
likely have calculated CRCL values of less
than 20 mL/min. In addition, the relation-
ship between CRCL and the degree of renal
failure is not linear, since a change from 
1 to 2 on the CRCL severity scale can indi-
cate a 50% decline in renal function. How-
ever, the difficulty of acquiring an accurate
CRCL test result precludes its use in com-
munity dental practice.
COAGULOPATHY AS A CONSEQUENCE OF
DISEASE:
Chronic renal failure
Over 200,000 people in the United States
have chronic renal failure (CRF) and a
resultant uraemia necessitating dialysis.16
In the UK, more than 500 patients/million
population are currently receiving treat-
ment, consuming 2% of the NHS budget.17
Causes of CRF include diabetes mellitus,
glomerulonephritis, and hypertension.
Patients with CRF can be hypercoagulable
due to depletion of proteins C, S, and
antithrombin III. Haemostasis in patients
with CRF is impaired principally as a result
of an ill-defined platelet dysfunction from
hyperviscosity and a defect in platelet
membrane glycoproteins (gp IIb-IIIa),
which play an important role in the adhe-
sion and primary platelet aggregation
stages of haemostasis (Table 1).18–21 These
glycoproteins serve as platelet membrane
receptor sites for binding fibronectin and
von Willebrand factor, which are necessary
for their proper function.20,22 The bleeding
time test result can be elevated in uraemic
patients with CRF in accordance with this
platelet defect, although this can be related
to anaemia as well.23 However, platelet
function is also increased in the setting of
nephrotic hyperproteinaemia (increased
protein in the blood) from kidney failure,
and platelet aggregation inhibitors (eg low-
dose aspirin) are often prescribed.24 The
kidneys are also a major source of erythro-
poietin, a key cytokine that induces
myeloid stem cells in the bone marrow to
differentiate into mature red cells.
Patients with CRF will either be in a
predialysis state or they will be on a regu-
lar dialysis programme. The determina-
tion of when dialysis patients have the
potential for clinically significant bleed-
Table 3 Laboratory tests used for evaluation of coagulopathies from systemic disease
Test Purpose Normal range
Prothrombin time (PT) Measure of extrinsic clotting cascade and 10–13 seconds
production of liver dependent clotting
factors
Platelet count Quantitative assessment of circulating 150,000–450,000/µl
platelets (eg leukemia, chemotherapy)
Creatinine clearance Determination of renal function 90–125 ml/min
(CRCL)
Bilirubin (conjugated) Determination of hepatic disease < 0.3 mg/dL
(< 5 µmol/L)
Albumin Chronic hepatic disease 3.5–4.5 g/dL
(35–45 g/L)
Table 4 Platelet counts and their influence on postoperative bleeding
Platelet count (per µl) Diagnosis Effect
150,000–450,000 Normal Unlikely cause of oral bleeding
100,000–150,000 Mild thrombocytopenia Potential increased oral bleeding from 
invasive procedures, but rare
50,000–100,000 Moderate thrombocytopenia Increased incidence of oral bleeding from 
procedures possible, but uncommon
25,000–50,000 Severe thrombocytopenia Problematic bleeding (even with 
venepuncture)
Elective invasive procedures should be 
deferred
< 25,000 Life threatening Spontaneous bleeding possible (usually 
< 10,000)
Only emergency invasive procedures and 
with haematology involvement
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ing from dental surgery is usually
straightforward, since they should not be
in a uraemic state following dialysis, and
therefore should not have problems with
platelet function. However, individuals
with renal failure, but not yet on dialysis
are more difficult to evaluate. Although
kidney function is monitored by the
blood urea, creatinine, and creatinine
clearance laboratory tests, it is not known
what these laboratory values must be to
represent a clinically significant risk for
oral bleeding. Finally, given the increased
incidence of hypertension in this patient
population, mean blood pressure should
be factored into the assessment of the
potential for prolonged bleeding. 
Hepatic failure
Hepatitis, hepatic cancer (primary or sec-
ondary), cirrhosis secondary to alcohol
abuse, and other diseases that destroy liver
tissue and decrease hepatic protein synthe-
sis, (except factor VIII and von Willebrand
factor) all result in a decrease in the clot-
ting factors necessary for haemostasis
(Table 1).25–27 In addition, obstructive
jaundice from cholestasis impedes Vitamin
K absorption, thus interfering with the pro-
duction of the Vitamin K-dependent fac-
tors II, VII, IX, and X, and proteins C and
S.28 Cirrhosis and portal hypertension can
also lead to an increased bleeding time, as
liver disease interferes with platelet distri-
bution and results in hypersplenism and
folate deficiency.
Liver function laboratory tests are
used to determine liver disease status, but
there is no definitive laboratory test that
determines the degree of hepatic failure,
such as the creatinine clearance test
serves for renal disease. Liver disease, if
severe enough, will manifest as an elevat-
ed prothrombin time (PT) test result, but
the correlation between PT test results
and oral bleeding has not been estab-
lished. Attempts have been made to use a
variety of laboratory test values and
physical findings to determine risk for
bleeding, and the Child-Pugh classifica-
tion scheme is the most common. More
recently, the modified Child-Pugh classi-
fication for cirrhosis has been described
(Table 2).26 This scheme uses ascites
(increased abdominal girth from fluid
retention), encephalopathy (from buildup
of proteins in the blood), bilirubin, albu-
min, and prothrombin time test results to
arrive at a numerical score. The value of
this scheme as a predictor of bleeding fol-
lowing dental surgery has not been deter-
mined, but it is unlikely that bleeding
would occur with a Modified Child Pugh
result of A or B, as Category B patients
would rarely have a PT greater than 4
seconds over the control value.
Bone marrow failure
There are several causes for the loss of
haemopoietic bone marrow cells (Table 1).
For example, the abnormal line of malig-
nant cells in leukaemia can suppress pro-
duction of normal blood cells, and the result
could be oral (gingival) bleeding as the first
indication of promyelocytic leukaemia.
Some cancer chemotherapy agents target
specific progenitor cells in the marrow (eg
leukaemic cells), and others suppress all
bone marrow cells, to include platelets. The
most important outcome of bone marrow
failure or damage, from the standpoint of
oral bleeding, is the impact on megakary-
ocytes, the progenitor cells for platelets.
Uraemia from renal failure and chronic
alcohol ingestion can damage the bone mar-
row, and results in low platelet counts and
an interference with platelet function.
There are other diseases and conditions
that predispose to oral bleeding, but they
are either rare (eg aplastic anaemia) and/or
their nature may preclude invasive dental
procedures in the community setting with-
out medical consultation. Malnutrition can
cause a vitamin K deficiency that results in
prolonged bleeding, and prolonged vita-
min C deficiency will produce scurvy, a
rare but life threatening disorder that pres-
ents with gingival swelling and bleeding.
DENTAL MANAGEMENT
CONSIDERATIONS
Fundamentals in patient management
In most situations of a single coagulopathy,
extractions and other similarly invasive
procedures can be managed safely in a
community dental practice. Careful surgical
technique, including an attempt at primary
wound closure and local haemostatic meas-
ures will usually suffice. Oxidised cellulose
tranexamic acid rinses,29–31 astringents (eg
aluminum chloride), microfibrillar colla-
gen, thrombin-soaked gauze,32 fibrin
sealant and adhesive,2,33 electrocautery,32
absorbable gelatin sponges, and amino-
caproic acid (EACA) to prevent clot lysis,
have all been suggested as aids to
haemostasis in this setting.3,34–39 Many of
these methods are based on studies with
flawed designs and therefore lack scientific
validity. A study of 69 patients undergoing
oral surgical procedures, with varying INR
values from warfarin had no cases of clini-
cally significant prolonged or excessive
bleeding with the use of both absorbable
gelatin sponges and fibrin sealant.2 How-
ever, prospective clinical studies suggest
that a surgical sponge with or without
sutures is all that is necessary.40 The usual
concentrations of epinephrine in local
anaesthetic (ie 1:80,000 in the UK) should
also help with intra- and post-operative
bleeding. In the case of single coagu-
lopathies, moderately invasive procedures
such as dental scaling, crown and bridge
procedures, and uncomplicated dental
extractions can be done safely without
alteration of anticoagulant medications or
preoperative blood transfusions. Patients
with multiple or more severe single coagu-
lopathies are best managed by dentists
familiar with these disorders and in set-
tings where blood products are available,
should they become necessary. Medical
advice should be sought for patients with
the following situations: 
1. Multiple coagulopathies;
2. Advanced uraemia without dialysis;
3. Platelet counts of less than 50,000;
4. Pre-liver transplant status;
5. Aplastic anaemia; and
6. High dose (ie myelosuppressive) cancer
chemotherapy. 
The fundamentals of the dental man-
agement of patients with coagulopathies
are covered elsewhere.1,38,41 What follows
are principles of patient management that
relate to the underlying disease process,
and which have varying scientific support. 
The degree to which renal, hepatic, and
bone marrow disease interfere with coagu-
lation following invasive dental procedures
is not well understood. Although we could
find no randomised, prospective studies, it
is unlikely that individuals whose renal
failure is well managed with dialysis would
be at increased risk for clinically signifi-
cant bleeding, even from multiple dental
extractions. However, patients with liver or
bone marrow failure, and especially those
with multiple coagulopathies, are at some
risk. Therefore, patients with a medical his-
tory suggestive of a coagulopathy from
systemic disease must be evaluated con-
cerning the need to alter their dental man-
agement. Based on the medical history,
patients may require specific laboratory
tests, and consideration should be given to
contacting the patient's medical practition-
er, or if appropriate, a haematologist. 
In the case of dialysis for CRF, patients
are heparinised for the time they are receiv-
ing dialysis, and they could be anticoagu-
lated to some degree for several hours
thereafter. Heparinisation, along with
chronic anticoagulation (eg aspirin, war-
farin), creates a multifactorial coagulopa-
thy that puts a patient at higher risk for
bleeding from dental procedures immedi-
ately following dialysis. Although the half-
life of heparin is approximately 4 hours,
dialysis is a long and fatiguing procedure,
and for this reason patients are better able
to tolerate dental care on a non-dialysis
day. On the other hand, the longer a patient
is from their last dialysis, the more likely
they are to have a coagulopathy from
08p439-445.qxd  17/09/2003  10:59  Page 443
PRACTICE
444 BRITISH DENTAL JOURNAL VOLUME 195 NO. 8 OCTOBER 25 2003
uraemia. Finally, use caution with drugs
that are cleared by the kidneys, such as an
increased plasma level of potassium from
penicillin, as they can build up to toxic
levels.
Patients with liver failure from any cause
are difficult to evaluate from the stand-
point of risk for oral bleeding. A relatively
small elevation of the prothrombin time
(PT) test (eg PT = 13–15) suggest significant
(ie > 50%) liver damage. There are various
methods for improving patient tolerance of
invasive procedures. Vitamin K (at doses of
10 mg IM) corrects hypoprothrombinemia
from malnutrition and biliary obstruction,
but not intrinsic liver disease. Fresh frozen
plasma will lower the prothrombin time,
and platelet transfusion addresses both
quantitative and qualitative problems. In
the case of more significant coagu-
lopathies, the approach to an invasive pro-
cedure may need to be adjusted according-
ly, and the patient should be observed
post-operatively in the surgery for a longer
time period than usual. Care should be
exercised with the use of narcotic anal-
gesics (eg morphine) and sedatives (eg
diazepam), as their duration is prolonged in
decompensated liver disease. As with
chronic renal failure, smaller doses should
be used for drugs that are metabolised by
the liver. In particular, avoid the use of
paracetamol in the presence of liver failure
and alcoholism, although doses of up to
4 g/day are allowable. Algorithms have
been proposed for the determination of risk
for bleeding from varying invasive proce-
dures, but it is important to recognise that
there are few if any reliable prospective
studies to provide firm guidelines for these
issues.38
Patients with bone marrow failure or
damage, who do not have another coagu-
lopathy, are of concern from the standpoint
of their platelet status, both quantitative
and qualitative. A platelet count test result
should be above 50,000 for elective and
moderately invasive procedures. Although
most textbooks suggest a risk of bleeding
with a platelet count below 50,000, in the
absence of an additional coagulopathy,
single tooth extractions can often be
accomplished with counts below this level
(eg > 30,000), but consultation with the
patient's haematologist is advised.
Risk from various dental procedures
The risk of bleeding from various invasive
dental procedures is a poorly understood
area of clinical practice, and it forms a con-
tinuum of relative risk from none to great.
It is clear that a simple restoration that does
not involve the gingiva is non-invasive
and poses little or no risk by comparison
with deep scaling and multiple extractions.
The difficulty lies in the middle ground of
invasiveness, (eg supragingival scaling,
extensive restorations). A long-standing
concern exists with block injections as
opposed to infiltration of local anaesthesia,
since it requires deeper invasion of the tis-
sues and the potential to invade muscle
and large vessels. As a general rule, inferior
dental block anaesthesia should be consid-
ered an invasive procedure, if only because
of the long-standing (but poorly docu-
mented) concern about bleeding in an area
that is difficult to control and which might
involve the airway. A combination of infil-
tration and intraligamentary anaesthesia
might be appropriate in cases of severe
coagulopathy, but only for extractions or
endodontic procedures, as permanent
damage to the neurovascular contents of
the pulp chamber could result from
restorative procedures following intraliga-
mentary injections. The spectrum of risks
in each of these scenarios may never be
fully established, but a combination of
common sense, an understanding of the
principles involved, clinical experience,
and an ability to manage the rare compli-
cation of bleeding allow for the least risk
to the patient.
Given the vascularity of the oral cavity,
some degree of intra- and post-operative
bleeding from surgical procedures is
expected. However, the incidence of clini-
cally significant intra- or post-operative
bleeding following a single tooth extrac-
tion is unusual or rare. In addition to
cost/benefit issues, dental practitioners
should avoid the discomfort, inconven-
ience and expense of unnecessary labora-
tory testing, specialty referral, and/or hos-
pitalisation. Few prospective clinical
studies exist to aid in the determination of
management protocols for patients with
acquired coagulopathies, and therefore cur-
rent clinical practice is often based on opin-
ion, historical precedent, case reports, and
false assumptions based on laboratory test-
ing.36,42 Clearly, high-quality research in
this area of dental practice is a high priority.
The authors would like to thank Philip C. Fox DDS,
Charles H. Packman MD, Mack Mitchell MD, and
George Hart MD for their help in reviewing this
manuscript. 
1. Patton L L, Ship J A. Treatment of patients with
bleeding disorders. Dent Clin North Am 1994; 38:
465-482.
2. Bodner L, Weinstein J M, Baumgarten A K. Efficacy of
fibrin sealant in patients on various levels of oral
anticoagulant undergoing oral surgery. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endod 1998; 86: 
421-424.
3. Souto J C, Oliver A, Zuazu-Jausoro I, Vives A,
Fontcuberta J. Oral surgery in anticoagulated patients
without reducing the dose of oral anticoagulant: A
prospective randomized study. J Oral Maxillofac Surg
1996; 54: 27-32.
4. Seward G R, Harris M, McGowan D A, Killey H C , Kay L
W. An Outline of Oral Surgery Parts I & II. Oxford:
Wright, 1998.
5. Friedlander A H, Mills M J, Gorelick D A. Alcoholism
and dental management. Oral Surg Oral Med Oral
Pathol 1987; 63: 42-46.
6. Lockhart P B, Schmidtke M A. Antibiotic
considerations in medically compromised patients.
Dent Clin North Am 1994; 38: 381-402.
7. Barber A, Green D, Galluzzo T, Ts'ao C. The bleeding
time as a preoperative screening test. Am J Med 1985;
78: 761-764.
8. Rodgers R P C, Levin J. Bleeding time revisited (letter
to the editor with response). Blood 1992; 79: 2495-
2497.
9. Bowie E J W, Fass D N, Owen C A, Jr. Hemostatic effect
of transfused Willebrand factor in porcine von
Willebrand's disease. Similarities to the human
disease. Haemostasis 1980; 9: 352-365.
10. Deykin D, Janson P, McMahon L. Ethanol potentiation
of aspirin-induced prolongation of the bleeding time.
N Engl J Med 1982; 306: 852-854.
11. Mielke C H, Jr. Aspirin prolongation of the template
bleeding time: Influence of venostasis and direction
of incision. Blood 1982; 60: 1139-1142.
12. Bashein G, Nessly M L, Rice A L, Counts R B, Misbach
GA. Preoperative aspirin therapy and reoperation for
bleeding after coronary artery bypass surgery. Arch
Intern Med 1991; 151: 89-93.
13. Hirsh J, Poller L, Deykin D, Levine M, Dalen J E. Optimal
therapeutic range for oral anticoagulants. Chest
1989; 95: 5S-11S.
14. NKF-DOQI Clinical Practice Guidelines for
Hemodialysis Adequacy. 1997. New York: National
Kidney Foundation. Ref Type: Pamphlet
15. Hakim R M, Depner T A, Parker T F, III. Adequacy of
hemodialysis. Am J Kidney Dis 1992; 20: 107-123.
16. Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998;
338: 1428-1437.
17. Feest T. Epidemiology and causes of chronic renal
failure. Savage C O S, Gaskin G, eds. Medicine — UK
Edition 27[6], 30-32. 1999. London: England, The
Medicine Publishing Company Ltd. Chronic Renal
Failure. Feest, T. Ref Type: Serial (Book,Monograph)
18. Gawaz M P, Dobos G, Spath M, Schollmeyer P,
Gurland H J, Mujais S K. Impaired function of platelet
membrane glycoprotein IIb-IIIa in end-stage renal
disease. J Am Soc Nephrol 1994; 5: 36-46.
19. Benigni A, Boccardo P, Galbusera M, Monteagudo J,
De Marco L, Remuzzi G et al. Reversible activation
defect of the platelet glycoprotein IIb-IIIa complex in
patients with uremia. Am J Kidney Dis 1993; 22: 
668-676.
20. George J N, Shattil S J. The clinical importance of
acquired abnormalities of platelet function. N Engl J
Med 1991; 324: 27-39.
21. Sreedhara R, Itagaki I, Lynn B, Hakim RM. Defective
platelet aggregation in uremia is transiently
worsened by hemodialysis. Am J Kidney Dis 1995; 25:
555-563.
22. Galbusera M, Benigni A, Paris S, Ruggenenti P, Zoja C,
Rossi C et al. Unrecognized pattern of von Willebrand
factor abnormalities in hemolytic uremic syndrome
and thrombotic thrombocytopenic purpura. J Am Soc
Nephrol 1999; 10: 1234-1241.
23. Livio M, Marchesi D, Remuzzi G, Gotti E, Mecca G, de
Gaetano G. Uraemic bleeding: role of anaemia and
beneficial effect of red cell transfusions. Lancet 1982;
November 6: 1013-1015.
24. Orth S R, Ritz E. The nephrotic syndrome. N Engl J Med
1998; 338: 1202-1211.
25. Cowan D H. Effect of alcoholism on hemostasis.
Semin Hematol 1980; 17: 137-147.
26. Petruff C A, Chopra S. Cirrhosis and portal
hypertension: An overview. In Friedman L S, Keeffe E B.
Maddrey W C, eds. Handbook of Liver Disease.133.
New York : Churchill Livingstone, 1998.
27. Kessler D A. Drug promotion and scientific exchange.
The role of the clinical investigator. N Engl J Med 1991;
325: 201-203.
28. Landefeld C S, Beyth R J. Anticoagulant-related
bleeding: clinical epidemiology, prediction, and
prevention. Am J Med 1993; 95: 315-328.
29. Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A.
Comparison of bleeding complications of warfarin
and warfarin plus acetylsalicylic acid: a study in 3166
outpatients. J Intern Med 1994; 236: 299-304.
30. Sindet-Pedersen S, Ramström G, Bernvil S, Blombäck
M. Hemostatic effect of tranexamic acid mouthwash
08p439-445.qxd  17/09/2003  10:59  Page 444
PRACTICE
BRITISH DENTAL JOURNAL VOLUME 195 NO. 8 OCTOBER 25 2003 445
in anticoagulant-treated patients undergoing oral
surgery. N Engl J Med 1989; 320: 840-843.
31. Borea G, Montebugnoli L, Capuzzi P, Magelli C.
Tranexamic acid as a mouthwash in anticoagulant-
treated patients undergoing oral surgery. An
alternative method to discontinuing anticoagulant
therapy. Oral Surg Oral Med Oral Pathol 1993; 75: 
29-31.
32. Ziccardi V B, Saini J, Demas P N, Braun T W.
Management of the oral and maxillofacial surgery
patient with end-stage renal disease. J Oral Maxillofac
Surg 1992; 50: 1207-1212.
33. Halfpenny W, Fraser J S, Adlam D M. Comparison of 
2 hemostatic agents for the prevention of
postextraction hemorrhage in patients on
anticoagulants. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 2001; 92: 257-259.
34. Vinckier F, Vermylen J. Blood loss following dental
extractions in anticoagulated rabbits: Effects of
tranexamic acid and socket packing. Oral Surg Oral
Med Oral Pathol 1985; 59: 2-5.
35. White R H, McKittrick T, Takakuwa J, Callahan C,
McDonell M, Fihn S et al. Management and prognosis
of life-threatening bleeding during warfarin therapy.
Arch Intern Med 1996; 156: 1197-1201.
36. Martinowitz U, Mazar A L, Taicher S, Varon D, Gitel S
N, Ramot B et al. Dental extraction for patients on oral
anticoagulant therapy. Oral Surg Oral Med Oral Pathol
1990; 70: 274-277.
37. Mulligan R, Weitzel K G. Pretreatment management
of the patient receiving anticoagulant drugs. J Am
Dent Assoc 1988; 117: 479-483.
38. Herman W W, Konzelman J L, Sutley S H. Current
perspectives on dental patients receiving coumarin
anticoagulant therapy. J Am Dent Assoc 1997; 128:
327-335.
39. Johnson W T, Leary J M. Management of dental
patients with bleeding disorders: Review and update.
Oral Surg Oral Med Oral Pathol 1988; 66: 297-303.
40. Blinder D, Manor Y, Martinowitz U, Taicher S. Dental
extractions in patients maintained on continued oral
anticoagulant. Comparison of local hemostatic
modalities. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 1999; 88: 137-140.
41. Surgical management of the primary care dental
patient on warfarin. 2001. Liverpool, England, North
West Medicines Information Centre. Ref Type: Generic
42. Rooney T P. General dentistry during continuous
anticoagulation therapy. Oral Surg Oral Med Oral
Pathol 1983; 56: 252-255.
ONLINE SUBMISSION to the British Dental Journal
The British Dental Journal at www.bdj.co.uk is pleased to be able to offer its authors the option
to submit their manuscripts online.
• Authors from anywhere in the world will be able to quickly and easily enter their contact
details into an online form, and attach their manuscript files, either as separate text and
graphics, or as an integrated file.
• Author files will be automatically converted into a PDF (Portable Document Format) file,
which can be approved by the author on screen prior to submission. Submissions will be
promptly acknowledged by e-mail. Editors and referees will then view the PDF on the
website — cutting out the time that manuscripts traditionally spend in the postal system.
• Authors who, for whatever reason, are unable to submit online can also benefit from the
timeliness of electronic peer review. Authors are encouraged to submit their manuscripts on
disk, or if necessary hard copy submissions can be converted into PDF files using high-
quality scanners.
• Making use of online submission and electronic peer review will enable us to speed up the
review process, providing a better and more efficient service to authors. 
For further information about submitting your paper electronically please e-mail:
k.maynard@bda.org
08p439-445.qxd  17/09/2003  11:00  Page 445
